Burleson & Company, LLC Genprex, Inc. Call Options Transaction History
Burleson & Company, LLC
- $384 Million
- Q4 2022
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding GNPX
# of Institutions
2Shares Held
600Call Options Held
0Put Options Held
0About Genprex, Inc.
- Ticker GNPX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,020,300
- Market Cap $48.5M
- Description
- Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incor...